

IRONWOOD PHARMACEUTICALS INC

Form 8-K

April 18, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

Current Report Pursuant to

Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

April 13, 2017

**IRONWOOD PHARMACEUTICALS, INC.**

*(Exact name of registrant as specified in its charter)*

**Delaware**

*(State or other jurisdiction  
of incorporation)*

**001-34620**

*(Commission File Number)*

**04-3404176**

*(I.R.S. Employer  
Identification Number)*

**301 Binney Street  
Cambridge, Massachusetts**

*(Address of principal  
executive offices)*

**02142**

*(Zip code)*

**(617) 621-7722**

*(Registrant's telephone number,  
including area code)*

## Edgar Filing: IRONWOOD PHARMACEUTICALS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

(b)

On April 13, 2017, Christopher T. Walsh, Ph.D. informed Ironwood Pharmaceuticals, Inc. (the Company) that he will transition off of the Company's board of directors, effective as of the date of the Company's 2017 annual meeting of stockholders (the Annual Meeting) to be held on May 31, 2017. As a result, Dr. Walsh's term of office as a Class III director of the Company will end as of the date of the Annual Meeting.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Ironwood Pharmaceuticals, Inc.**

Dated: April 18, 2017

By: /s/ Halley E. Gilbert  
Name:  
Title:

Halley E. Gilbert  
Senior Vice President, Chief  
Legal Officer, and Secretary